Sept 26 (Reuters) - The European Medicines Agency (EMA)

recommended suspending the marketing authorization for Pfizer's ( PFE )

sickle cell disease drug Oxbryta on Thursday.

EMA said new data raise serious concerns about the safety of

Oxbryta and added that the authorization, marketing and supply

of the medicine be suspended until all the available data have

been assessed in the ongoing review.

Late on Wednesday, Pfizer ( PFE ) said it was withdrawing Oxbryta

from all markets where it is approved, citing risks of a painful

complication and deaths.